A Research Study to Compare the Effect of Insulin Degludec and Insulin Glargine on Blood Sugar Levels in People With Type 2 Diabetes - the SWITCH PRO Study



Status:Recruiting
Conditions:Diabetes, Diabetes
Therapuetic Areas:Endocrinology
Healthy:No
Age Range:18 - Any
Updated:4/6/2019
Start Date:October 2, 2018
End Date:December 30, 2019
Contact:Novo Nordisk
Email:clinicaltrials@novonordisk.com
Phone:(+1) 866-867-7178

Use our guide to learn which trials are right for you!

A Randomised, Cross-over, Open-label, Multi-centre Trial Comparing the Effect of Insulin Degludec and Insulin Glargine 100U/mL, With or Without OADs in Subjects With Type 2 Diabetes Using Flash Glucose Monitoring

This study compares the effect on blood sugar levels of two medicines: insulin degludec and
insulin glargine in people with type 2 diabetes. Participants will be treated with insulin
degludec and insulin glargine during two different periods. Which treatment participants get
first is decided by chance. Both medicines are approved for use in humans and available on
the market. They can already be prescribed by participants' doctors. Participants will get
pre-filled insulin pens to inject these insulins with. The study will last for about 41
weeks. Participants will visit the clinic 13 times and have 27 phone calls with the study
doctor or study staff. At 12 of the clinic visits they will take blood samples. In order to
evaluate the changes in participants' blood sugar level over time, participants will be asked
to wear a small (35 millimetres (mm) x 5 mm) sensor on the back of participants' upper arm 3
times during the study. Each time participants must wear the sensor for 2 weeks. This sensor
is called FreeStyle Libre Pro®. It has a very small tip which is 0.4 mm thick and is inserted
5 mm under participants' skin. Please note that participants will not be able to see the
sensor readings while wearing it. The study doctor will show participants the readings when
participants return to the clinic. Participants will be asked to fill in a diary in between
visits. Participants will have contact with the study doctor or study staff each week. This
is to adjust the dose of participants' study medicines and to ensure that participants are
well. Women cannot take part if pregnant, breast-feeding or plan to become pregnant during
the study period.


Inclusion Criteria:

- Male or female, age greater than or equal to 18 years at the time of signing informed
consent

- Diagnosed with type 2 diabetes mellitus greater than or equal to 180 days prior to the
day of screening

- Subjects fulfilling at least one of the below criteria:

- Experienced at least one severe hypoglycaemic episode within the last year prior to
screening (according to the American Diabetes Association definition, January 2018)*

- Moderate renal impairment defined as estimated glomerular filtration rate value of
30-59 mL/min/1.73 m^2 as defined by Kidney Disease Improving Global Outcomes 2012 at
screening

- Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's
questionnaire question 8 at screening

- Treated with insulin for more than 5 years

- Episode of hypoglycaemia (defined a glucose alert value of 70 mg/dL (3.9 mmol/L) or
less, i.e., Level 1) within the last 12 weeks prior to screening visit

- Treated with any basal insulin greater than or equal to 90 days prior to the day of
screening with or without any of the following anti-diabetic drugs:

- Metformin

- Dipeptidyl peptidase-4 inhibitor

- Sodium-glucose co-transporter 2 inhibitor

- Alpha-glucosidase-inhibitors (acarbose)

- Thiazolidinediones

- Marketed oral combination products only including the products listed above

- HbA1c less than or equal to 9.5% (80 mmol/mol) at screening confirmed by central
laboratory analysis

- Body mass index less than or equal to 45 kg/m^2 *Hypoglycaemia associated with severe
cognitive impairment requiring external assistance for recovery

Exclusion Criteria:

- Treatment with any medication for the indication of diabetes or obesity other than
stated in the inclusion criteria within the past 90 days prior to the day of
screening. However, intermittent bolus insulin treatment for periods of no longer than
14 days are permitted prior to the day of screening

- Anticipated initiation or change in concomitant medications known to affect weight or
glucose metabolism (e.g., treatment with orlistat, thyroid hormones, or
corticosteroids)

- Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by
a pharmacologically pupil-dilated fundus examination performed by an ophthalmologist
or another suitably qualified health care provider within the past 90 days prior to
screening or in the period between screening and run-in
We found this trial at
32
sites
New Windsor, New York 12553
?
mi
from
New Windsor, NY
Click here to add this to my saved trials
Amarillo, Texas 79106
?
mi
from
Amarillo, TX
Click here to add this to my saved trials
Boston, Massachusetts 02115
?
mi
from
Boston, MA
Click here to add this to my saved trials
Bradenton, Florida 34201
?
mi
from
Bradenton, FL
Click here to add this to my saved trials
?
mi
from
Calgary,
Click here to add this to my saved trials
Chandler, Arizona 85224
?
mi
from
Chandler, AZ
Click here to add this to my saved trials
Cincinnati, Ohio 45229
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Cooper City, Florida 33024
?
mi
from
Cooper City, FL
Click here to add this to my saved trials
Dakota Dunes, South Dakota 57049
?
mi
from
Dakota Dunes, SD
Click here to add this to my saved trials
Fresno, California 93702
?
mi
from
Fresno, CA
Click here to add this to my saved trials
Greenville, North Carolina 27834
?
mi
from
Greenville, NC
Click here to add this to my saved trials
Hamden, Connecticut 06518
?
mi
from
Hamden, CT
Click here to add this to my saved trials
Hollywood, Florida 33024
?
mi
from
Hollywood, FL
Click here to add this to my saved trials
Kalispell, Montana 59901
?
mi
from
Kalispell, MT
Click here to add this to my saved trials
Kerrville, Texas 78028
?
mi
from
Kerrville, TX
Click here to add this to my saved trials
Lancaster, California 93534
?
mi
from
Lancaster, CA
Click here to add this to my saved trials
Lexington, Kentucky 40503
?
mi
from
Lexington, KY
Click here to add this to my saved trials
Louisville, Kentucky 40213
?
mi
from
Louisville, KY
Click here to add this to my saved trials
Nashville, Tennessee 37203
?
mi
from
Nashville, TN
Click here to add this to my saved trials
New Port Richey, Florida 34652
?
mi
from
New Port Richey, FL
Click here to add this to my saved trials
Northridge, California 91325
?
mi
from
Northridge, CA
Click here to add this to my saved trials
Orlando, Florida 32804
?
mi
from
Orlando, FL
Click here to add this to my saved trials
Pelzer, South Carolina 29669
?
mi
from
Pelzer, SC
Click here to add this to my saved trials
Pembroke Pines, Florida 33026
?
mi
from
Pembroke Pines, FL
Click here to add this to my saved trials
Poway, California 92064
?
mi
from
Poway, CA
Click here to add this to my saved trials
San Antonio, Texas 78224
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
Skokie, Illinois 60077
?
mi
from
Skokie, IL
Click here to add this to my saved trials
Statesville, North Carolina 28625
?
mi
from
Statesville, NC
Click here to add this to my saved trials
?
mi
from
Toledo, OH
Click here to add this to my saved trials
Topeka, Kansas 66606
?
mi
from
Topeka, KS
Click here to add this to my saved trials
Tucson, Arizona 85704
?
mi
from
Tucson, AZ
Click here to add this to my saved trials
Van Nuys, California 91405
?
mi
from
Van Nuys, CA
Click here to add this to my saved trials